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Abstract Tissue engineering and the tissue engineering model have shown promise in improving
methods of drug delivery, drug action, and drug discovery in pharmaceutical research for the attenuation
of the central nervous system inﬂammatory response. Such inﬂammation contributes to the lack of
regenerative ability of neural cells, as well as the temporary and permanent loss of function associated
with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and traumatic brain
injury. This review is focused speciﬁcally on the recent advances in the tissue engineering model made by
altering scaffold biophysical and biochemical properties for use in the treatment of neurodegenerative
diseases. A portion of this article will also be spent on the review of recent progress made in extracellular
matrix decellularization as a new and innovative scaffold for disease treatment.
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1.
1.1.

Introduction
Background

Neurodegenerative diseases and brain disorders have been some of
the targets for pharmaceutical research. There are an estimated
5.4 million cases of Alzheimer's disease and 1 million cases of
Parkinson's disease in the US as of 2016. It is projected that the
number of individuals suffering from Alzheimer's will increase to
16 million by 2050, while approximately 60,000 new diagnoses of
Parkinson's occur every year in the US alone1,2. The substantial
increase in the number of occurrences of these and other
neurodegenerative diseases will cost billions of dollars and require
countless hours of personal medical care worldwide. Due to the
tremendous burden to countries, families, and individuals brought
on by these diseases, an emphasis has been placed on improving
current therapies and ﬁnding novel remedies to treat these
disorders.
One challenge associated with the treatment of neurodegenerative diseases is the attenuation of neuroinﬂammation brought on
by these disorders. This inﬂammatory response is thought to be a
main driving force behind the progression of these diseases, which
contributes to the loss of neural cells and lack of functional
recovery after disease onset3. Promising results in the treatment of
many neurodegenerative diseases have been obtained during
preliminary trials by mitigating neural inﬂammation afﬁliated with
these diseases4–6. Because of these ﬁndings, one area of focus is to
explore the use of known and novel anti-inﬂammatory compounds
for the treatment of neurodegenerative disorders, in hopes of
ﬁnding more effective therapies for individuals suffering from
these ailments. Even though anti-inﬂammatory compounds are
promising therapies, pharmaceutical research still needs to ﬁnd
more feasible methods to screen for potential anti-inﬂammatory
agents as well as to ﬁnd more effective ways to deliver these drugs
to sites of neuroinﬂammation and degeneration. Advancements
made in 3-dimensional (3D) tissue mimics, by employing tissue
engineering principles, have improved preclinical drug screening
trials7,8; the results of which have provided unique platforms for
the enhancement of drug delivery to areas of need9–12.
This article reviews recent progress in pharmaceutical science
made speciﬁcally by application of the tissue engineering model
and 3D tissue mimics. Utilization of this model in the advancement of drug screening procedures and drug delivery methods will
be thoroughly reviewed as a novel approach to beneﬁt the
treatment of neurological diseases. A novel decellularization
technique will also be summarized as a 3D culture material that
mimics the natural ECM of the brain. This new approach will
further open the door to continued progress in solving the
neurodegenerative disease crisis by providing more reliable drug
screening and toxicity results from preclinical trials. In this way,
the use of tissue engineering principles will enhance pharmaceutical and neurodegenerative disease research.

1.2.

may contribute to the self-propelling nature of neurodegenerative
diseases3,13–16.
Resting, or inactivated microglia, are dynamic cells that
constantly survey their surroundings by extending and contracting
processes protruding from their cell body. These processes are able
to detect minute change in their environment and in this way are
able to identify and respond to signals or foreign objects that
require an immune response17. In an attempt to remove harmful
substances, this immune response is often associated with the
release of many pro-inﬂammatory mediators that are modulated by
activated microglia, such as superoxide, nitric oxide, tumor
necrosis factor-alpha (TNF-α), and inﬂammatory prostaglandins
that induce inﬂammation in the central nervous system16. The
purpose of these pro-inﬂammatory mediators is to rid the central
nervous system of invading pathogens or foreign objects, but these
mediators are also toxic to neural cells and can promote neural cell
damage and death.
Upon damage or death of neural cells, soluble neuron-injury
factors/cytokines such as µ-calpain, MMP3, α-synuclein, and
neuromelanin are often released from neural cells and are received
by receptors on the surface of microglial cells. These soluble
neuron-injury factors activate more microglial cells or serve to
prolong the activated state of previously activated microglial cells.
These activated microglial cells continue to release pro-inﬂammatory mediators that further damage neural cells that, in turn,
continue to activate microglial cells. This cycle, termed reactive
microgliosis, chronically activates the microglial cell inﬂammatory
response and self-propels neurotoxicity (Fig. 1).
This heightened inﬂammatory response and state of reactive
microgliosis has been commonly observed in neurodegenerative
diseases such as Parkinson's disease,3 Alzheimer's disease14,
amyotrophic lateral sclerosis18, and traumatic brain injury15,19. Due
to the progressive nature of these and other neurodegenerative
diseases, reactive microgliosis has been suspected as a main
contributor to the progression and lack of functional recovery
associated with neurodegenerative diseases. A consequence of
reactive microgliosis is that an emphasis has been placed on
screening for compounds that exhibit anti-inﬂammatory effects for
the treatment of neurodegenerative diseases.

Role of microglia in neurodegenerative diseases

Immune systems have become targets of emerging pharmaceutical
research, including that of the central nervous system (CNS).
Unlike macrophages that serve as the immune cells for the rest of
the body, microgliaare the resident immune cells uniquely of the
CNS and thus have many important functions in the brain.
Unregulated and prolonged activation of these immune cells

Figure 1 Reactive microgliosis perpetuates neuron damage and
inﬂammation. Stimulation of microglia with pro-inﬂammatory triggers, as well as direct neuron damage, results in microglial activation
and the release of neurotoxic factors. After damaged by a proinﬂammatory trigger or direct neurotoxin, the neuron releases microglial activators, which propagates the cycle.
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1.3.

The tissue engineering model

Tissue engineering is the application of engineering principles to
treat, or replace, damaged tissues and organs. The tissue engineering model employs the use of 3D matrices to culture cells, and to
produce living tissues, which mimic the morphology and function
of what naturally occurs in vivo. These tissue mimics can be
exploited for studies of disease propagation and progression, drug
discovery and compound screening, and even tissue repair and
replacement. The use of organoids, 3D scaffolds, and decellularization techniques are viable ways to create 3D materials for use in
tissue speciﬁc research.
One common method for producing tissue mimics is the use of
3D organoids. An organoid is deﬁned as “an in vitro 3D cellular
cluster derived exclusively from primary tissue, embryonic stem
cells, or induced pluripotent stem cells (iPSCs), capable of selfrenewal and self-organization, while exhibiting similar organ
functionality as the tissue of origin”20 (“Cell Culture”). An
advantage of the organoid model is the ability to study disease
development and progression due to the ability of organoids to
mimic the morphology and functionality of the tissues which they
are derived from. A study by Lancaster et al.21 took advantage of
the organoid model to better determine the cause of hypoplasia in
patients suffering from microcephaly. This study showed that nonfunctional CDK5RAP2 genes were a likely cause of premature
neural differentiation, resulting in hypoplasia of the organoid
cells21. Another beneﬁt of this model is the potential for developing more personalized medicine by culturing organoids from
healthy and diseased tissues of patients. By using the organoid
system, it is possible to screen for potential compounds that will
affect the diseased tissue with minimal side effects to healthy
tissues20. The organoid model is also being used for the study of
the Zika virus and its effects on human brain development22,23.
A second approach for the creation of tissue mimics is to seed
cells onto a 3D matrix, or to disperse cells into a liquid hydrogel
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which will form into a 3D scaffold during the polymerization
process24 (Fig. 2 “Engineered Materials”). These scaffolds are
formed from synthetic, or natural, polymers and the chemical and
physical properties of the scaffold, such as porosity, stiffness, and
incorporation of bioactive molecules, can easily be altered to ﬁt the
needs of the seeded cells. The beneﬁt of this method is the ability
to customize the microenvironment in which cells are cultured.
Recently, advances in 3D printing have made the creation of
printed matrices for tissue engineering possible. Speciﬁcally, 3D
printed scaffolds are under investigation for use in bone tissue
engineering purposes25, but may have applications for softer
tissues.
A novel alternative to conventional culture techniques is to use
a decellularization method to obtain material for a 3D matrix. This
method involves removal of cells from native tissues or organs,
while maintaining extracellular matrix (ECM) integrity and keeping important bioactive molecules intact26,27 (Fig. 2 “AnimalBased Materials”). This method provides a 3D microenvironment
for seeded cells with most of the necessary chemical cues intact for
healthy growth and development.
When applying tissue engineering principles to neural tissues,
the mechanical properties of the brain must be considered when
determining an appropriate method to use. Brain tissue is a soft
tissue with an elastic modulus in the hundreds of pascals range,
while other tissues in the human body have much higher elastic
moduli28,29. It has been shown that cells respond to the resistance,
or stiffness, of the substrate on which they are cultured30, with the
substrate stiffness directly affecting the proliferation and differentiation of stem cells to neural cells29.
As opposed to other tissues in the body, the primary immune
cells of the brain are microglial cells. Microglial cells are beneﬁcial,
but have been are known to produce pro-inﬂammatory molecules
that may contribute to disease progression33. Acceptable tissue
engineering models of the human brain should include microglial
cells to more accurately reﬂect inﬂammatory pathways in the brain.

Figure 2 The tissue engineering model and different ways 3D microenvironments are formed. Gray scaffolds represent the absence of cells, pink
scaffolds represent the presence of seeded human stem cells, and the yellow scaffold represents the presence of animal cells before tissue
decellularization. Microscopic images in the engineered materials section, cell culture section, and animal-based materials section were adapted
with permission from Mandal et al.31, Lancaster et al.21, and De Waele et al.32, respectively.
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2.

Drug candidates for neurodegenerative disease

2.1.

Anti-inﬂammatory drug candidates

Many compounds and bioactive molecules have shown activity in
in vitro and in animal models against neuroinﬂammation and
reactive microgliosis. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) are a class of compounds that are well known to have
anti-inﬂammatory, analgesic, and antipyretic effects. As such, they
show great promise in the treatment of inﬂammation associated
with neurodegenerative diseases. It is well known that NSAIDs
help to regulate inﬂammation in the body by inhibiting the activity
of cyclooxygenase 1 (COX 1), cyclooxygenase 2 (COX 2), and
prostaglandin (PG) biosynthetic enzymes34,35. PGs are mediators
of inﬂammation and they are synthesized in vivo from arachidonic
acid by the action of COX enzymes.
Of particular interest in the central nervous system is the
synthesis of prostaglandin E2 (PGE2), which is the major
prostaglandin associated with the presence of inﬂammation in
the brain and spinal cord36. Several NSAIDs have shown promise
for the attenuation of the inﬂammatory response by reducing the
levels of PGE2 in circulation, in animal models, once an insult to
the brain has been experienced4 (Table 15,37–47). As prostaglandins
are mediators of inﬂammation in the brain, the effective inhibition
of their synthesis and release helps to reduce inﬂammation brought
on by activated microglia. These anti-inﬂammatory effects have
been displayed in disease models of Alzheimer's disease48 and
Parkinson's disease49, and may be applied to other neurodegenerative diseases as well.
Other studies have been conducted to determine the effectiveness of natural compounds in the treatment of neuroinﬂammation.
Although little is known about their mechanisms, many natural
compounds show great promise in the treatment of neuroinﬂammation (Table 1). One study experimented with the anti-inﬂammatory effects of torilin, a compound isolated from the stem and
root bark of Ulmus davidiana var. japonica, and determined that it
was effective in reducing iNOS levels, COX 2 levels, and IL-1β
levels in murine BV2 microglial cells after exposure to lipopolysaccharides (LPS)40. Another study focused on the anti-

Table 1

inﬂammatory effects of macelignan, a compound isolated from
Myristica fragrans Houtt, on primary culture of rat microglial cells
after exposure to LPS. This study showed that macelignan
effectively reduced the concentrations of three known pro-inﬂammatory molecules: interleukin 6 (IL-6), tumor necrosis factor-α
(TNF-α), and nitrite (NO) in rat microglial cultures after exposure
to LPS in vitro41. A thorough review by Pangestuti and Kim6
demonstrated that many different species of marine algae have
shown neuroprotective effects in vivo and in vitro by acting as
antioxidants, by reducing neuroinﬂammation, and by inhibiting
neuronal cell death6,42,44. Eicosanoyl-5-hydroxytryptamide (EHT),
a component in coffee, also exhibited anti-inﬂammatory and
neuroprotective effects in MPTP models of Parkinson's disease
in mice after exposure to LPS45. Additionally, multiple compounds isolated from the root bar of Lycium chinense have shown
to suppress the production of NO in LPS-induced BV2 cells46. In
these ways, many natural compounds show promise in the
treatment of neuroinﬂammation and neurodegenerative diseases.
Plasmalogens have also shown promise in the treatment of
inﬂammation in neurodegenerative diseases (Table 1), especially
Alzheimer's disease. Plasmalogens are glycerophospholipids that
have a vinyl ether moiety on the ﬁrst carbon of the glycerol
backbone and are known to play important roles in membrane
ﬂuidity and cellular processes. A study was performed by
Ifuku et al.5 to determine the effect of plasmalogens on LPS-induced
microglial activation in adult mice brains. As expected, LPS
injections in the prefrontal cortex (PFC) of adult mice signiﬁcantly
increased the number of activated microglial cells as well as the
amount of pro-inﬂammatory mediators such as IL-1β, TNF-α,
reactive oxygen species, and reactive nitrogen species. It has been
seen that administration of plasmalogens after LPS injection in the
PFC of mice attenuated the microglial activation to control levels of
mice that did not receive LPS injections. A side effect of the
attenuated microglial activation was a signiﬁcant decrease in the
concentration of pro-inﬂammatory mediators back to control levels5.
Due to the vinyl ether moiety located on the ﬁrst carbon of the
glycerol backbone, it is thought that plasmalogens have antioxidant
effects50,51 that may contribute to their anti-inﬂammatory properties
by regulating free radical concentrations in the brain.

Effect of different anti-inﬂammatory compounds on pro-inﬂammatory mediators in the CNS.

Drug

Effect

Status

Indomethacin (NSAID)
Piroxicam (NSAID)
Flurbiprofen (NSAID)
Paracetamol (NSAID)
Acetylsalicylic acid (NSAID)
NS-398 (NSAID)
Torillin

Reduced the PGE2 level by 50% in rats (1 nmol/L)37,38
Reduced the PGE2 level by 50% (0.1 µmol/L37,38
Reduced the PGE2 level by 50% (0.1 µmol/L)38,39
Reduced the PGE2 level by 50% (7.6 µmol/L)38
Reduced the PGE2 level by 50% (10 µmol/L) 38
COX-2 inhibitor: reduced the PGE2 levels by 50% (1–5 nmol/L)38
Reduced neurotoxic factors after LPS exposure in murine
BV2 microglial cells40
Reduced neurotoxic factors after LPS exposure in rat microglial cultures41
Reduced pro-inﬂammatory mediators in murine BV2 and HT22 cell lines42–44
Reduced pro-inﬂammatory mediators in cultured primary microglia
after LPS exposure45
Suppress production of NO in BV2 cells46
Attenuation of microglia activation and of pro-inﬂammatory mediators
in mice PFC5
Reduce levels of pro-inﬂammatory intermediates in mice47

Approved drug
Approved drug
Approved drug
Approved drug
Approved drug
Chemical approved for research
Natural product/drug candidate

Macelignan
Marine algae
EHT
Lycium chinense
Plasmalogens
PHPB

Natural product/drug candidate
Natural product/drug candidate
Natural product/drug candidate
Natural product/drug candidate
Natural product/drug candidate
Phase II clinical trials
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A novel neuroprotective compound, potassium 2-(1-hydroxypentyl)-benzoate (PHPB), was shown to reduce levels of proinﬂammatory intermediates after LPS treatment in mice, and has
shown potential in the treatment of Alzheimer's disease and
ischemic stroke47. PHPB is currently in phase II clinical trial for
ischemic stroke in China47.
Even though many compounds show potential for treatment of
neurodegenerative diseases in initial experiments, suitable models
must still be developed to further explore a compound's effect on
disease progression and native tissues before it can proceed to
expensive clinical trials.

2.2.

3D tissue models as drug screening tools

A speciﬁc challenge facing pharmaceutical companies and drug
discovery is the high attrition rate of potential therapeutic
compounds as they go from the in vitro to in vivo stage of drug
research and development. It is estimated that less than 8% of
drugs that enter phase I clinical trials will make it to market and
this high attrition rate is made worse when factoring in that
average costs to complete clinical trials range from 0.8 to
1.7 billion dollars8,52,53. Due to the high monetary cost of getting
a new drug approved for use by the FDA, it is necessary to screen
and dismiss compounds that are potentially ineffective or toxic as
early in the compound evaluation process as possible54; often
carried out through in vitro cell culture models. As a result, during
the early stage, it is crucial to utilize models as close as possible to
the in vivo counterpart.
Traditionally, 2-dimensional (2D) cell cultures have been used
as an initial means to determine a compound's potential use as a
novel drug. Although this 2D method is convenient, research has
shown that the use of a 2D cell culture has potentially signiﬁcant
drawbacks producing misleading toxicological data55. It has been
seen experimentally that cells grown in 2D cultures exhibit
different morphologies, polarity, receptor expression, extra-cellular
matrix interaction, cell–cell interactions, and other chemical and
physical properties, when compared to what is observed
in vivo54,56. These differences in cell structure and behavior in
2D cultures have been attributed to the failure of numerous
compounds during in vivo experiments that showed promise in
preclinical trials. However, 3D cell culturing techniques, used
often in tissue engineering applications, have shown much
stronger similarities between the structure and function of cultured
cells versus those found in native tissues. The ability of cells
grown in 3D cultures to more closely mimic those grown in native
environments24 makes them more effective for use in drug
screening preclinical trials.
The use of 3D drug screening techniques for neural tissues is
still in its early stage, but substantial research has been done on its
use in drug screening for cancer treatment and other tissues57,
using similar principles. For example, Imamura et al.7 compared
the use of 2D versus 3D culture models to test the effectiveness of
paclitaxel, doxorubicin, and 5-ﬂuorouracil in the treatment of
breast cancer7. In their study, breast cancer cells on 3D culture
plates, which more closely mimicked in vivo conditions, tended to
form more dense multicellular spheroids when compared to the 2D
cultures. The formation of these denser spheroids made the breast
cancer cell lines grown in 3D cultures more resistant to both
paclitaxel and doxorubicin when compared to 2D cultures in drug
sensitivity studies. A second study by DesRochers et al.8 sought to
model nephrotoxicity in 3D cultures while comparing them to 2D
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cultures. Human renal cortical epithelial cells were cultured in a
3D matrix consisting of a 1:1 ratio of Matrigel to rat tail collagen.
It was shown that cells cultured in the 3D matrix more closely
mimicked an in vivo-like phenotype when compared to 2D
cultures of the same cell type. Both the 3D and 2D cultures were
exposed to three compounds known to cause nephrotoxicity
in vivo, cisplatin, gentamicin, and doxorubicin, to determine the
concentration of each compound that induces 50% toxicity in the
cultured cells LD50. LD50 levels showed signiﬁcantly increased
sensitivity to the nephrotoxins in the 3D culture when compared to
the 2D culture, indicating that the 3D model is more useful for the
detection of nephrotoxicity and drug screening, as it more closely
mimics in vivo tissues. 3D models for other tissues have shown
signiﬁcant differences in phenotype, when compared to 2D
cultures58–60, further illustrating the beneﬁt of using 3D engineered
microenvironments for the screening of anti-inﬂammatory compounds in the treatment of neurodegenerative diseases.
One obstacle that must be overcome to fully utilize 3D tissue
models is to create a bioactive scaffold with speciﬁc biological
molecules that will better mimic native environments and enhance
cell growth. Synthetic scaffolds, while easy to produce, are
biologically inert and do not interact with cultured cells in
chemically or biologically beneﬁcial ways. It is possible to
chemically modify 3D scaffolds and drug screening platforms to
include growth factors, proteins, signaling molecules, and other
chemical entities to better mimic native tissues. Examples of
molecules used in tissue engineering applications are vascular
endothelial growth factor (VEGF)61 and platelet derived growth
factor (PDGF)62, which stimulate blood vessel formation and
encourage normal cell growth and division, and the peptide
sequence arginine-glycine-aspartic acid63 (RGD), which is used
to improve cell attachment and encourage regular cell behavior.
Molecules, such as collagen and laminin may also be included in
3D scaffolds to design matrix that more closely mimics the ECM
of neural cells64.
3.

Chemical modiﬁcation of scaffold materials

An advantage of using 3D tissue engineering scaffolds for drug
screening applications is the ability to customize a cell's microenvironment by applying chemical modiﬁcations to the scaffold.
These modiﬁcations allow the creation of a speciﬁc cellular niche
that enables the user to create a microenvironment with similarities
to natural tissues. By customizing the environment in which cells
are cultured, it is possible to encourage cellular phenotype and
behavior that is comparable to those found in vivo. Advances in
organic chemistry principles, such as click chemistry, have made
the chemical modiﬁcation of 3D polymeric scaffolds simple and
effective in the creation of customized cellular niches to be used in
drug screening applications.
3.1.

Chemical modiﬁcation using click chemistry

Since the emergence of click chemistry in 2001, it has become a
promising technique to engineer the architecture and function
of 3D materials65. The term click chemistry was introduced in
2001 and was used to describe chemical reactions that are highyield, with by-products removable without chromatography,
regiospeciﬁc and stereospeciﬁc; can be conducted in aqueous or
benign reaction conditions, are orthogonal to other organic
synthesis reactions, and are amendable to a wide variety of starting
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compounds66. Of the click reactions known to date, the most
common for use in scaffold modiﬁcation are alkyne-azide
cycloadditions (AAC), Diels-Alder reactions (DA), thiol-ene
coupling, and thiol-Michael additions63,67,68. The thiol-mediated
reactions are particularly useful as their application for surface
modiﬁcation and biofunctionalization of polymers has become
commonplace63.
A study performed by Luo et al.69 sought to demonstrate the
effectiveness of a thiol-maleimide click reaction for immobilizing
a glycine-arginine-glycine-aspartic acid-serine peptide sequence (a
ﬁbronectin peptide fragment) onto a 3D agarose hydrogel. A
photolabile matrix was created by covalent modiﬁcation of agarose
with S-2-nitrobenzyl-cysteine, which readily release free thiols
when exposed to UV light. These free thiols are then able to react
with thiol-reactive biomolecules through Michael addition. Free
thiols were reacted with a maleimide-terminated RGD peptide
sequence to immobilize it on to the agarose hydrogel. This agarose
hydrogel functionalized with an immobilized RGD sequence was
shown to promote the extension and migration of primary rat
dorsal root ganglia cell in vitro63,69. Another application of the
thiol-maleimide click reaction was performed by Aizawa et al.61
for the functionalization of an agarose-sulphide hydrogel with
VEGF165 gradients. Primary endothelial cells cultured within
these hydrogels exhibited tip and stalk cell morphologies as seen
in vivo61. Using a similar reaction, Aizawa et al.62 immobilized
PDGF-AA on thiol-containing channels in an agarose hydrogel.
This model was able to preferentially differentiate neural stem/
progenitor cells into oligodendrocytes, when they were cultured on
the agarose/PDFG-AA hybrid62,70. The success of these three
models indicate the potential to more closely mimic in vivo
conditions by functionalizing 3D scaffolds using click chemistry.
A thiol-ene mediated click reaction has also been successfully
employed to pattern an RGD peptide sequence onto a PEG
hydrogel. These immobilized RGD sequences also proved to
inﬂuence cell morphology and behavior of cultured cells to behave
more like their in vivo counterparts71,72. It has also been shown
that exploitation of thiol-mediated reactions to immobilize multiple
peptide sequences onto a single hydrogel allows the creation of
more customizable cellular microenvironments for drug screening
purposes71–73. A beneﬁt of utilizing the thiol-ene is that essentially
any functional group chemically linked to a small molecule thiol
can be used in a thiol-ene reaction to produce a functionalized
scaffold66. This has tremendous value as it may become a means
to better mimic in vivo conditions using 3D scaffolds and tissue
engineering principles.
The ability to simulate in vivo environments with appropriate
cell phenotype and behavior by utilizing principles of click
chemistry and compound immobilization may provide superior
models for drug screening trials.

4.

Drug delivery methods

Another signiﬁcant challenge to overcome in the treatment of
neurodegenerative diseases in the CNS is the delivery of therapeutics across the blood–brain barrier (BBB). The BBB is formed from
a series of tight junctions mainly composed of endothelial cells,
while other cell types such as astrocytes, pericytes, macrophage,
ﬁbroblasts, neuronal cells, basal membranes, and microglia are also
included74. The purpose of the BBB is to protect the brain from
pathogens and disease by restricting the passage of most substances
into the CNS75,76. In fact, it is estimated that nearly 100% of all

large molecule drugs and nearly 98% of all small molecule drugs do
not freely cross the BBB without assistance77–80. With no direct
way to transport the majority of pharmaceuticals across the BBB, it
has become increasingly important to apply tissue engineering
principles to create novel drug delivery vehicles for the treatment
of neurodegenerative diseases.
3D scaffolds can also be effectively used in the treatment of
neurodegenerative diseases as vehicles for the delivery of antiinﬂammatory therapeutics to sites of chronic inﬂammation following implantation to the brain. There are multiple ways in which
these scaffolds may be utilized, but two of the more common
methods of drug delivery from 3D scaffolds are diffusion-based
methods and immobilized drug delivery systems. These two
systems are different in how drugs are loaded to the scaffold.
With diffusion-based methods, the release of desired drugs is
regulated by the properties of the scaffold while immobilized
systems utilize covalent bonding of drugs directly to the interior/
exterior of the scaffold surface. Immobilized drug delivery rate is
then determined by the degradation rate of the 3D material9.

4.1.

Diffusion-based methods

One prevalent method of diffusion-based drug delivery is the
direct loading of the scaffold for delivery. This method involves
loading of bioactive compounds directly into the scaffold during
gelation. Drug release rates are then determined by concentration
gradients and the intrinsic properties of the fabricated scaffold,
which affect the diffusion rate of the drug out of the scaffold. An
experiment by Burdick et al.81 used a PEG hydrogel-based
delivery system for the delivery of ciliary neurotrophic factor
(CNTF) to stimulate neurite outgrowth after disruption of central
nervous system tissues. Human CNTF was incorporated into the
polymer before curing of the hydrogel, and 3D hydrogels with
CNTF inside were formed after polymerization. It was shown
experimentally that the PEG hydrogels had an initial ‘burst’ of
CNTF, followed by a more sustained release of the growth factor
ranging from 21 to 74 days, depending on mechanical properties
of the hydrogel. Tests were then run to determine whether or not
the CNTF released from the scaffold retained its biological
activity, by exposing retinal explants to the released neurotrophins
to enhance neurite outgrowth. The CNTF retained its biological
activity as evidenced by inducing neurite outgrowth in retinal
explants when compared to control retinal explants without
exposure to CNTF81. Other studies have also been done to
determine the release proﬁles and effects of other bioactive
compounds on CNS models when released from 3D scaffolds82–
84
. These 3D scaffolds call for direct implantation for local
delivery of therapeutics to the brain, but due to their small size
and physical properties, they require only small disruptions of the
BBB to be effective. In some cases, it is possible to inject uncured
scaffolds directly into the brain, to allow the polymer to solidify in
its target area. A beneﬁt of this approach is minimal disruption of
the BBB10,85.
A second diffusion-based method is through the encapsulation
of bioactive compounds into microspheres/nanocarriers ﬁrst,
which can then be integrated into tissue engineered scaffolds or
function independently as drug delivery devices. Synthetic polymers are commonly used to encapsulate bioactive compounds, and
can be formed into microspheres/nanocarriers, using established
methods86. A study by Wang et al.11 determined the release proﬁle
of BDNF and VEGF released from a poly(lactic-co-glycolic acid)
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(PLGA) microsphere system for drug delivery applications. Unlike
the direct use of scaffold based delivery systems, the PLGA
microsphere system exhibited no initial ‘burst’ of compound, but
provided a slow and mostly linear release proﬁle during the 6-day
testing period. The amount of encapsulated BDNF and VEGF
released was estimated to be 20%–30% of the total amount
contained in the microspheres. The neuron cell survival rate
determined by the activity of the released BDNF and VEGF was
then veriﬁed by treating neurons exposed to glutamate with the
released growth factors; with growth factor controls. It has been
shown that growth factors incorporated in microspheres did not
lose their biological activity upon release, when compared to
growth factor controls. Similar microsphere/nanocarrier devices
have been implemented for the release of anti-inﬂammatory agents
in neural tissues for the treatment of neurodegenerative disease87,88, delivery of doxorubicin for the treatment of liver
cancer89, and the delivery of paclitaxel to the lymphatic system
for cancer treatment90, including brain tumors91. These microsphere/nanocarrier drug delivery vehicles can be administered
locally with small disruptions to the BBB85, or systemically
without BBB disruption by modifying the polymer surface to
make them more BBB permeable92–94.
Delivery systems have also been designed to combine the
advantages of scaffold-based delivery with microsphere-based
delivery to further customize compound release proﬁles for
speciﬁc drug delivery applications. The combination of scaffolds
with various microspheres makes it possible to design a delivery
that can release multiple bioactive compounds with differing
release proﬁles. This model is an ideal method when treatment
with multiple bioactive compounds is beneﬁcial. An example of
this method was used by Richardson et al.12 for the initiation of
angiogenesis in a rat model. A polymeric system consisting of a
porous poly(lactide-co-glycolide) (PLG) scaffold containing
VEGF, with PLG microspheres containing PDGF incorporated
inside the scaffold, was designed for the dual delivery of both
growth factors simultaneously. The results from this experiment
showed distinct release proﬁles for each growth factor from the
combined system as well as an increase in blood vessel density
and maturation, when compared to single growth factor treatment
models. This type of multiplex model has also shown promise in
the treatment of neurological disorders81.

4.2.

Immobilized drug delivery

A third approach in the delivery of therapeutics via 3D scaffolds is
the immobilization of drugs chemically onto the scaffold surface.
This process often involves covalent bonding between the desired
drug and the scaffold itself. This immobilization technique can
provide more control over drug delivery, as the release rate is
primarily modulated by enzymatic or chemical cleavage of the
polymer-drug bond95. One model of particular interest in the
treatment of neuroinﬂammation and neurodegenerative diseases
was put forth by Nuttelman et al.96 when they covalently attached
dexamethasone, a known anti-inﬂammatory agent, to a poly(ethylene-glycol) (PEG) scaffold. The covalent attachment was facilitated
via a lactide linkage, with the number of linkages directly
inﬂuencing the release rate of the drug from the PEG scaffold. As
the number of lactide linkages between the drug and scaffold
increased the drug release rate also increased. Dexamethasone was
likewise shown to preserve its biological activity96. Covalent
attachment was used by Chun et al.10 as well to tether paclitaxel,
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an anti-tumor drug investigated for use in the treatment of brain
tumors, to a poly(organophosphazene) polymer. This paclitaxelpolymer conjugate proved to be more effective in treating tumors
long term, when compared to free paclitaxel in vivo. The authors
attributed this increased in vivo activity to the controlled and
sustained release of paclitaxel through the hydrolytic cleavage of
the paclitaxel-polymer bond10. Similar immobilization approaches
have been used to adhere growth factors on to polymeric scaffolds
for prolonged delivery to neural cells97–99.

5.

Future directions

To improve the use of 3D scaffolds for drug screening and drug
delivery purposes, it is required to alter the chemical and
biophysical properties of the materials to better suite of the needs
of the cultured cells and native tissues. More recently, tissue
engineering has evolved to include decellularization techniques to
create 3D materials from cell extracellular matrix (ECM) materials
complete with growth factors, proteins, and signaling molecules26,100. Though current pharmaceutical research with decellularized tissues has often involved matrix modiﬁcation with
natural or synthetic materials101,102 to re-condition the ECM, there
is a potential to retain native scaffold structures for the generation
of tissue engineering products, which can be used in compound
screening and drug delivery applications.
Decellularization, the removal of cells from tissues or organs, is
a method which has been successfully used in aspects of tissue
engineering and regenerative medicine for application in transplantation, drug development, and personlized medicine26,27.
Common methods of decellularization involve a combination of
physical and chemical treatments including agitation, freeze-thaw
cycles, trypsin, and detergents. Ideally, decellularization will
effectively remove all cellular and nuclear materials while minimizing damage to the ECM scaffold's tissue-speciﬁc microarchitecture or three-dimensional texture26,27.
The tissue-speciﬁc ECM scaffold's microarchitecture is composed of extracellular components (collagens, glycosaminoglycans, elastin, ﬁbrin, etc.) and growth factors in their proper spatial
distribution and ratios. The tissue-speciﬁc microenvironment
allows for more efﬁcient cell proliferation, attachment, and
differentiation27. Retention of these tissue-speciﬁc microenvironments seems to allow natural ECM scaffolds to be superior to their
synthetic counterparts27,32,103–105. Further, a key beneﬁt of decellularization is retention of innate vascular networks essential for
oxygen and nutrient delivery100. An overarching challenge to 3D
cell culture systems is the delivery of nutrients and disposal of
waste. Cellular spheroids, for example, are a simple but useful 3D
tissue model that is limited to a few hundred micrometers, beyond
which, a necrotic core develops106. Naturally derived ECM
scaffolds with retained vasculature hold promise for increasing
the size at which tissue engineering can occur. Additionally, as
components of the ECM are normally conserved across species,
xenogeneic ECM scaffolds can be developed from a variety
sources and well tolerated by seeded cells26. In review, naturally-derived ECM scaffolds developed via decellularization have
the potential to show appropriate microarchitecture and functional
mechanical properties; be compatible, bioactive, cell supportive,
readily available, and inexpensive, as well as present functional
vasculature for oxygen and nutrient delivery27.
The development and use of decellularization in tissue engineering for drug development and screening purposes is ongoing.
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Perhaps the most widely used naturally-derived ECM scaffold,
Matrigel (reconstituted basement membrane) is processed from the
Engelbreth-Holm-Swarm (EHS) sarcoma to produce a soluble and
sterile extract that forms a 3D gel107. Because Matrigel is derived
from a tumor of the basement membrane, and promotes cell
growth, it is particularly beneﬁcial in drug screening and development108–110. The production of 3D cell cultures using ECM
scaffolds developed through decellularization has been, or is
currently being, demonstrated in cardiac, adipose, hepatic, pleural,
vascular, skeletal muscle, neuronal, and renal tissues111–118.
An extremely exciting approach to drug testing using tissue
engineering is the creation of organoids and organ-on-a-chip/bodyon-a-chip systems111,112,117,119–121. Organoids, simpliﬁed miniature
organs, can be produced from primary tissues as well as embryonic
stem cells or induced pluripotent stem cells20. Because the behavior
of cells are controlled by the microenvironment, organoids frequently utilize naturally-derived or synthetic ECM substrates, small
molecules, and growth factors to ﬁne tune the self-renewal/
differentiation of stem cells and self-assembly of cells in organoids122. As a near 3D physiological model, organoids are capable
of biological processes including tissue renewal, mutation, and
metabolism, and conversion of prodrugs into an active metabolite20,123. Body-on-a-chip systems have been able to capitalize on
the interplay of several connected organoids to closely replicate size
relationships of organs, blood distribution, and blood ﬂow represented in human physiology111,112,123. Additionally, using a patient's
own cells to create organoids used in body-on-chip systems will
lead to advances in personalized medicine and potentially eliminate
the use of animals in preclinical trials111,123.
6.

Conclusions

In summary, the use of the tissue engineering model and 3D
mimicking materials and their applications will enhance the ﬁelds
of pharmaceutical science and pharmacology as pharmaceutical
scientists strive to solve the neurodegenerative disease problem.
Used as drug screening and drug delivery tools, 3D models may
open the door to improved and novel treatments that will promote
the recovery and quality of life of individuals afﬂicted with these
diseases. More recent advancements in the tissue engineering
model using decellularization techniques will further augment drug
screening models by providing better tissue mimics to experiment
with chemical effects on neural cells and toxicity in connected
tissues. There is much work that needs to be done in order to cure
these diseases, but application of the tissue engineering model will
go a long way in bridging the gap between treating these diseases
and striving to manage the symptoms expressed in individuals.
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